Mitochondria don't just produce energy, they also send signals, and MOTS-c is the clearest example of that idea in the research peptide world. It's one of the few peptides actually encoded by mitochondrial DNA itself, which is a genuinely unusual origin story worth understanding before wading into what it's claimed to do.
What MOTS-c is
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide first characterized by Changhan Lee, Pinchas Cohen, and colleagues. What makes it unusual is where it comes from: almost all signaling peptides are encoded by nuclear DNA, but MOTS-c is encoded within the mitochondrial genome's 12S ribosomal RNA region, making it one of the only known hormones with a mitochondrial, not nuclear, genetic origin (Cell Metabolism, 2015).
What's actually been studied
- Metabolic effects in mice. The foundational 2015 study found that MOTS-c reduced diet-induced obesity and improved insulin sensitivity and glucose uptake in mice fed a high-fat diet, an effect tied to activation of the AMPK energy-sensing pathway (Cell Metabolism, 2015, mouse study).
- Stress-response signaling. A follow-up mouse study found that under metabolic stress, MOTS-c translocates to the cell nucleus and appears to directly regulate the expression of nuclear genes involved in antioxidant response, an unusual retrograde signaling role for a mitochondria-derived molecule (Cell Metabolism, 2018, mouse and cell-culture study).
- Exercise and aging. A University of Southern California research summary describes mouse studies in which MOTS-c administration increased running capacity and was associated with better muscle function in older mice, framed by the researchers as evidence for an "exercise-mimetic" effect (USC Leonard Davis School, 2021, mouse study).
- Human correlational data. A systematic review and meta-analysis looked at how naturally circulating MOTS-c levels in humans correlate with metabolic states, rather than testing MOTS-c as an administered treatment. This is observational human data about the body's own MOTS-c levels, not interventional trial data on injecting or dosing the peptide (systematic review and meta-analysis, PMC).
Where the evidence is thin
I could not find a published human interventional trial, meaning a study that actually administered MOTS-c to people and measured an outcome, in the course of researching this post. What exists on the human side is correlational: studies associating a person's own naturally circulating MOTS-c levels with metabolic health markers, which is a genuinely different kind of evidence than a dosed clinical trial. Nearly everything establishing an actual effect of administered MOTS-c (the obesity, insulin sensitivity, nuclear signaling, and exercise-capacity findings) comes from mouse studies. That's earlier-stage than SS-31, which at least has multiple human trials on record, even unsuccessful ones. If you see MOTS-c discussed online as an established human "exercise mimetic" or metabolic therapy, that claim is running well ahead of what's actually been tested in people.
The regulatory picture
MOTS-c is not FDA-approved for any use and has not, as far as the published literature shows, completed human clinical trials for any condition. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
The mitochondrial-DNA origin story here is genuinely interesting, and I understand why a peptide that seems to let mitochondria talk directly to the rest of the cell generates excitement. But the evidence base right now is mice plus human correlation data, not human dosing trials. Those are different tiers of evidence, and the gap between them is exactly where I'd want more research before taking any of the metabolic or exercise claims as settled. If you're researching this compound, keep species and study design in view for every claim you read, since "improved insulin sensitivity in mice" and "improves human metabolic health" get blurred together constantly in online discussion of this peptide specifically.
Sources
- The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance, Cell Metabolism, 2015 (mouse study)
- The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress, Cell Metabolism, 2018 (mouse and cell-culture study)
- MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism, PubMed
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation, PMC
- MOTS-c Functionally Prevents Metabolic Disorders, PubMed
- "Exercise protein" doubles running capacity, restores function and extends healthy lifespans in older mice, USC Leonard Davis School, 2021 (mouse study, university research summary)
- The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysis, PMC (human correlational data)
- MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases, PMC (review)
Sourcing for research
If you're sourcing MOTS-c for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.